Catalyst Brief

← Calendar

Readoutin 103d

Janssen-Cilag Ltd. — Guselkumab

Phase 3 primary completion: A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease.

Date
Mar 2027
Type
Readout
Indication
Fistulizing Crohns Disease

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.